ACAD
34.45
-0.48
-1.37%
AEMD
3.75
+0.1
+2.74%
APRI
2.29
+0.03
+1.33%
ARNA
1.45
+0.02
+1.40%
ATEC
2.07
-0.61
-22.76%
CNAT
4.59
+0.19
+4.32%
CRXM
0.2
-0.01
-4.76%
CYTX
1.64
+0.03
+1.86%
DXCM
76.08
-0.82
-1.07%
GNMK
13.14
+0.12
+0.92%
HALO
13.46
-0.03
-0.22%
ILMN
167.69
-0.1
-0.06%
INNV
0.11
0.00
+1.63%
INO
5.95
+0.03
+0.51%
ISCO
1.65
-0.1
-5.71%
ISIS
57.56
0.00
0.00%
LGND
103.79
-0.28
-0.27%
LPTN
2.93
0.00
0.00%
MBVX
2.51
+0.06
+2.45%
MEIP
1.57
+0.03
+1.95%
MNOV
5.81
+0.01
+0.17%
MRTX
5.1
-0.05
-0.97%
MSTX
0.107
+0.01
+9.744%
NBIX
41.5
-0.22
-0.53%
NUVA
74.295
-0.255
-0.342%
ONCS
1.25
-0.01
-0.79%
ONVO
3.01
0.00
0.00%
OREX
4
0.00
0.00%
OTIC
13.1
-0.05
-0.38%
QDEL
21.675
+0.365
+1.713%
RCPT
231.96
0.00
0.00%
RGLS
1.25
0.00
0.00%
RMD
71.31
+0.02
+0.03%
SPHS
2.58
+0.03
+1.18%
SRNE
4.2
+0.05
+1.20%
TROV
1.15
+0.15
+15.00%
VICL
2.13
-0.05
-2.29%
VOLC
18
0.00
0.00%
ZGNX
10.4
+0.05
+0.48%
ACAD
34.45
-0.48
-1.37%
AEMD
3.75
+0.1
+2.74%
APRI
2.29
+0.03
+1.33%
ARNA
1.45
+0.02
+1.40%
ATEC
2.07
-0.61
-22.76%
CNAT
4.59
+0.19
+4.32%
CRXM
0.2
-0.01
-4.76%
CYTX
1.64
+0.03
+1.86%
DXCM
76.08
-0.82
-1.07%
GNMK
13.14
+0.12
+0.92%
HALO
13.46
-0.03
-0.22%
ILMN
167.69
-0.1
-0.06%
INNV
0.11
0.00
+1.63%
INO
5.95
+0.03
+0.51%
ISCO
1.65
-0.1
-5.71%
ISIS
57.56
0.00
0.00%
LGND
103.79
-0.28
-0.27%
LPTN
2.93
0.00
0.00%
MBVX
2.51
+0.06
+2.45%
MEIP
1.57
+0.03
+1.95%
MNOV
5.81
+0.01
+0.17%
MRTX
5.1
-0.05
-0.97%
MSTX
0.107
+0.01
+9.744%
NBIX
41.5
-0.22
-0.53%
NUVA
74.295
-0.255
-0.342%
ONCS
1.25
-0.01
-0.79%
ONVO
3.01
0.00
0.00%
OREX
4
0.00
0.00%
OTIC
13.1
-0.05
-0.38%
QDEL
21.675
+0.365
+1.713%
RCPT
231.96
0.00
0.00%
RGLS
1.25
0.00
0.00%
RMD
71.31
+0.02
+0.03%
SPHS
2.58
+0.03
+1.18%
SRNE
4.2
+0.05
+1.20%
TROV
1.15
+0.15
+15.00%
VICL
2.13
-0.05
-2.29%
VOLC
18
0.00
0.00%
ZGNX
10.4
+0.05
+0.48%
Home » Archive by Category

Xconomy

Cidara Antifungal Flunks in Phase 2 Clinical Trial, Sinking Shares

February 21, 2017 – 9:24 am

Cidara Therapeutics is halting work on an experimental topical antifungal drug designed to treat vaginal yeast infections after the compound wasn’t better than the current standard of care in a Phase…

[[Click headline to continue reading.]]

Bio Roundup: CRISPR Drama, Marathon and PhRMA, the Price of Vision & More

February 17, 2017 – 5:45 am

News may be coming out of Washington, DC, at a breakneck pace, but concrete plans regarding the future of the nation’s healthcare system, the FDA, and the pharmaceutical industry have been much…

[[Click headline to continue reading.]]

Dermata Secures $10M in Combined Financing for Skin Treatments

February 16, 2017 – 9:12 pm

[Corrected 2/17/17, 9:41 am to differentiate Silicon Valley Bank’s loan from private investment.] Dermata Therapeutics, a San Diego development-stage biotech advancing new treatments for…

[[Click headline to continue reading.]]

With $20M, UCSD Spinout Jecure To Press New Attack On NASH

February 15, 2017 – 4:55 am

[Updated 2/15/17, 8:10 pm ET. See below.] Liver disease is challenging for doctors because it can develop without symptoms, making diagnosis difficult without removing cells for examination. For…

[[Click headline to continue reading.]]

Dear Tom Price: Bundled Payments Help Patients and Reduce Costs

February 11, 2017 – 3:00 am

With all the talk of repealing Barack Obama’s Affordable Care Act (ACA), people have been taking a closer look at what the law has done for our healthcare system. It turns out the ACA is about a lot…

[[Click headline to continue reading.]]

Senate Confirms Price for HHS, But Stock Deals Still Raise Questions

February 10, 2017 – 5:22 am

The Senate confirmed Tom Price as Secretary of the U.S. Department of Health and Human Services early Friday morning by a 52-47 vote that, as expected, fell largely on party lines. Price is an…

[[Click headline to continue reading.]]

Bio Roundup: Travel Ban Block, Gilead Shock, Dean Kamen Talk & More

February 10, 2017 – 3:35 am

The biotech community pushed back against President Donald Trump’s order to block travelers and refugees this week, and not much later, a federal court did, too. Patient advocates have scored…

[[Click headline to continue reading.]]

Often Advocates Of Faster FDA, Patient Groups Wary Of Trump Deregulation

February 10, 2017 – 3:30 am

In the biomedical world, perhaps the biggest question looming over President Donald Trump’s upcoming pick for Food and Drug Administration commissioner is how drastically that person will help…

[[Click headline to continue reading.]]

Xconomy Is Growing: We Need Great Salespeople in SF, Texas, and NY

February 9, 2017 – 9:59 am

Since Xconomy’s founding nearly a decade ago, we have grown from a single bureau in Boston to having editors covering 11 innovation clusters around the United States. And over this time, we have…

[[Click headline to continue reading.]]

Biotech Leaders Sign Letter Condemning Trump’s Travel Ban

February 7, 2017 – 6:55 am

The blowback from U.S. business leaders to President Trump’s travel ban continues—today from a throng of biotech executives. This morning, 165 U.S. biotech leaders have signed a letter voicing…

[[Click headline to continue reading.]]